Evelo Biosciences' Potential COVID-19 Treatment Progresses into Phase II Study

Evelo Biosciences' Potential COVID-19 Treatment Progresses into Phase II Study

Source: 
BioSpace
snippet: 

Evelo Biosciences, along with Rutgers University and Robert Wood Johnson University Hospital, is driving toward a Phase II study of an investigational treatment for hospitalized patients with newly diagnosed COVID-19.

The company is aiming a drug initially under development for psoriasis at COVID-19 based on early clinical data that shows its efficacy in blunting the production of multiple inflammatory cytokines – the same kind that many serious COVID-19 patients are dealing with.